|
AU2006201066A1
|
|
Immunodeficiency recombinant poxvirus
|
|
AU2002300582B2
|
|
Immunodeficiency Recombinant Poxvirus
|
|
AU5768501A
|
|
Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses
|
|
AU7219800A
|
|
Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
|
|
AU6247000A
|
|
Recombinant poxvirus-calicivirus (rabbit hemorrhagic disease virus (RHDV)) compositions and uses
|
|
AU5941300A
|
|
Recombinant poxvirus-cytomegalovirus, compositions and uses
|
|
AU3125299A
|
|
Immunodeficiency recombinant poxvirus
|
|
US6017537A
|
|
Formyl methionyl peptide vaccine adjuvant
|
|
AU1606799A
|
|
Recombinant vaccinia constructs expressing feline il-2, compositions and methodsof use thereof
|
|
WO9929872A1
|
|
Nucleic acid molecules encoding canine parainfluenza type 2f and hn proteins
|
|
US6267965B1
|
|
Recombinant poxvirus—cytomegalovirus compositions and uses
|
|
AU5645798A
|
|
Recombinant virus immunotherapy
|
|
US5990091A
|
|
Vectors having enhanced expression, and methods of making and uses thereof
|
|
US6004777A
|
|
Vectors having enhanced expression, and methods of making and uses thereof
|
|
AU1001197A
|
|
TROVAC fowlpox virus recombinants comprising heterologous inserts
|
|
AU6051396A
|
|
Measles virus recombinant poxvirus vaccine
|
|
US5997878A
|
|
Recombinant poxvirus-cytomegalovirus, compositions and uses
|
|
WO9621727A1
|
|
Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
|
|
AU4700096A
|
|
Immunogenic compositions containing recombinant attenuated poxviruses expressing HTLV antigens
|
|
US5858373A
|
|
Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
|
